Good morning, everyone, and welcome to the middle of the week. Congratulations on making it this far and remember there are only a few more days until the weekend arrives. So keep plugging away. After all, what are the alternatives? While you ponder the possibilities, we invite you to join us for a delightful cup of stimulation. Remember that no prescription is required. Meanwhile, here is the latest menu of tidbits to help you on your way. Have a wonderful day and please do stay in touch …
Celgene (CELG) is in talks to buy Juno Therapeutics (JUNO) in what would be its second big deal of 2018, The Wall Street Journal reports. Should a deal come to pass, Celgene would enter the pioneering field of chimeric antigen receptor therapy, or CAR-T, providing a further boost in the market for drugs treating multiple myeloma and other blood cancers. Recently, Gilead Sciences (GILD) paid more than $10 billion for Kite Pharma and its CAR-T technology. “While we are rarely fans of high premium takeovers, this deal probably makes sense for Celgene,” writes Leerink analyst Geoff Porges.
About the Author Reprints
http://alph.st/pd7bf702 Buying out Juno will definitely boost Celgene’s cancer portfolio.